Relay Therapeutics, Inc. (RLAY)
| Market Cap | 2.46B |
| Revenue (ttm) | 15.36M |
| Net Income (ttm) | -276.48M |
| Shares Out | 189.21M |
| EPS (ttm) | -1.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,614,752 |
| Open | 14.81 |
| Previous Close | 14.95 |
| Day's Range | 12.84 - 15.02 |
| 52-Week Range | 2.67 - 17.32 |
| Beta | 1.58 |
| Analysts | Strong Buy |
| Price Target | 18.90 (+45.16%) |
| Earnings Date | May 5, 2026 |
About RLAY
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Kα, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and αGal chaperone for Fabry diseases. It also develops R... [Read more]
Financial Performance
In 2025, Relay Therapeutics's revenue was $15.36 million, an increase of 53.44% compared to the previous year's $10.01 million. Losses were -$276.48 million, -18.13% less than in 2024.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for RLAY stock is "Strong Buy." The 12-month stock price target is $18.9, which is an increase of 45.16% from the latest price.
News
Relay Therapeutics Transcript: Study result
The zovegalisib/atirmociclib/fulvestrant triplet showed a 44% ORR and favorable tolerability in heavily pretreated metastatic breast cancer patients, supporting advancement to a phase III frontline trial targeting PI3Kα-mutated, endocrine-sensitive patients. Regulatory discussions and trial initiation are planned for early next year.
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-tre...
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies...
Relay Therapeutics' Cancer Drug Hits 11.1-Month Progression Free Survival - What Does This Means For Pretreated Breast Cancer Patients?
The data revealed on Monday that the 400mg BID fed regimen of zovegalisib demonstrated a median progression-free survival (PFS) of 11.1 months in heavily pre-treated patients with PI3Kα-mutated, HR+/H...
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast...
Relay Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference
The company is advancing a mutant-selective PI3K alpha inhibitor, zovegalisib, in metastatic breast cancer and vascular anomalies, with key data readouts expected this year and in 2026. Strong cash reserves support operations through 2029, and the pipeline is positioned for multiple late-stage catalysts.
Relay Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Key updates include imminent data releases for zovegalisib in breast cancer and vascular anomalies, with a focus on demonstrating differentiated efficacy and safety. Enrollment in pivotal trials is progressing, and the company is targeting large, underserved patient populations with potential for accelerated approval.
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026 Breast cancer triplet data and frontline Phase 3 plans expected to be announced i...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies ...
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies ...
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies ...
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib ...
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025
Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with P...
Relay Therapeutics Transcript: Jefferies London Healthcare Conference 2025
Execution of phase III trials for a PI3K alpha mutant selective inhibitor is progressing, with strong confidence in achieving superior PFS over current standards. Competitive landscape analysis highlights efficacy and safety differentiation, while pipeline expansion into vascular malformations and other indications is supported by robust financial resources.
Relay Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
RLY-2608 is advancing as a selective PI3Kα inhibitor with strong efficacy and tolerability in breast cancer and vascular malformations. The program is well-funded, strategically positioned against competitors, and targets significant commercial opportunities in both oncology and rare diseases.
Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates
Continued focused execution of RLY-2608 clinical trials in PI3Kα-mutated breast cancer and vascular malformations Appointed Lonnel Coats and Habib Dable, former biotech CEOs with launch and commercia...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies ...
Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025
CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...
Relay Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
RLY-2608, a PI3K mutant-selective inhibitor, is showing strong efficacy and safety in metastatic breast cancer and is being advanced in vascular malformations, both representing multi-billion dollar opportunities. The AI-enabled platform drives productivity, with several programs in the clinic.
Relay Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
RLY-2608 shows strong efficacy and safety in PIK3CA-mutated breast cancer, with a phase III trial underway and promising results in key subpopulations. The commercial opportunity is significant, and expansion into vascular malformations and other cancers is planned.
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies ...
Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates
Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3 ReD...
Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...
Relay Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference
The company is advancing its PI3K alpha selective inhibitor RLY-2608 into a pivotal phase 3 trial for breast cancer, supported by strong clinical data and a robust cash runway. Expansion into vascular malformations and other programs is ongoing, with a focus on execution and commercialization.